

Disclosures and Conflict of Interest (COI) Mitigation Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: Simon Fung-Kee-Fung, Ruth O'Regan, MD; Rahul Seth, DO; Tracey O'Connor, MD, and the staffs of the Empire State Hematology and Oncology Society and Physicians' Education Resource®, LLC.

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Shareholder	Other
Mark Burkard, MD, PhD	Abbvie, Arcus, Apollomics, Elevation Oncology, Endeavor, Genentech, Puma, Loxo Oncology, Seagen	Novartis, Strata Oncology			Investigational, unapproved, or off-label use of drugs: Tucatinib, neratinib, ipatasertib, capivasertib,
Ajay Dhakal	Celcuity, Puma	AstraZeneca, Gilead, WebMD, OncLive			
Shipra Gandhi, MD		AstraZeneca			
Ruth O'Regan	Puma, Novartis	AstraZeneca, Pfizer, Genomic Health, Biotheranostics, Novartis, Lilly, Puma Biotechnology, Genentech, Immunomedics, MacroGenics			
Seth Wander, MD, PhD	Eli Lilly, Genentech, Nuvation Bio, Pfizer, Regor Therapeutics	Foundation Medicine, Hologic, Biovica, Eli Lilly, Pfizer, Puma Biotechnology, Veracyte	Eli Lilly, Guardant Health, 2ndMD		
Anna Weiss	Institution, Myriad Labs, Inc				

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.